Shanghai Jmt-bio Inc.

This study is testing a new combination of drugs (KN026 plus chemotherapy, with or without enlonstobart) against the current standard treatment for people with advanced HER2-positive stomach cancer that cannot be removed by surgery. It aims to see if the new combination works bet…

This study is testing whether a new drug called JSKN003 works better than standard treatments for people with advanced HER2-positive colorectal cancer that has stopped responding to common chemotherapy drugs. The trial will involve 123 adults whose cancer has spread and who have …

This clinical trial is testing whether a new drug called SYS6090, when combined with standard chemotherapy or other targeted therapies, is safe and effective for people with advanced lung cancer. The study will enroll about 600 adults with either non-small cell or small cell lung…

This large study aims to see if a new combination of targeted drugs (KN026 and HB1801) with chemotherapy works better than the current standard treatment to keep HER2-positive breast cancer from returning after surgery. It will involve about 1,800 patients who have had surgery bu…